Who Paid My Doc
Daniela Matijevich
Podiatrist, Primary Podiatric Medicine Chesterton, IN Doctor of Podiatric Medicine
NPI 1386104826 CMS profile 11335336
601 Gateway Blvd N, Chesterton, IN 46304
General payments
$1,426
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Daniela Matijevich of Chesterton, IN is reported in the CMS Open Payments database as having received $1,426 across 73 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 65th percentile of Podiatrist, Primary Podiatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $631 | 27 | |
| 2024 | General | $273 | 15 | |
| 2023 | General | $413 | 26 | |
| 2022 | General | $109 | 5 |
Beside peers
- Daniela Matijevich
- Podiatrist, Primary Podiatric Medicine median
- Middle half of Podiatrist, Primary Podiatric Medicine
- National median
In program year 2025, general payments to Daniela Matijevich were reported at $631. Among 368 Podiatrist, Primary Podiatric Medicine profiles paid that year, the median was $232 and the middle half received between $88 and $586.
Show as a table
| Year | Daniela Matijevich | Podiatrist, Primary Podiatric Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $166 | $51–$513 | $163 |
| 2020 | $0 | $108 | $33–$249 | $114 |
| 2021 | $0 | $147 | $52–$377 | $132 |
| 2022 | $109 | $188 | $66–$551 | $149 |
| 2023 | $413 | $195 | $70–$509 | $160 |
| 2024 | $273 | $209 | $59–$508 | $164 |
| 2025 | $631 | $232 | $88–$586 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 12 drugsPart D claims
280
Drug cost
$2,802
Branded share of claims
24.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ciclopirox Ciclopirox Olamine | Brand | 28 | $1,026 | |
| Terbinafine Hcl | Generic | 26 | $316 | |
| Pregabalin | Generic | 15 | $283 | |
| Doxycycline Hyclate | Generic | 20 | $244 | |
| Methylprednisolone | Generic | 62 | $237 | |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | Brand | 15 | $152 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 26 | $152 | |
| Gabapentin | Generic | 15 | $119 | |
| Tramadol Hcl | Generic | 16 | $112 | |
| Cephalexin | Generic | 22 | $109 |
The 10 drugs with the highest cost, of 12 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 63 billing codesPaid by Medicare
$382,711
Medicare patients
325
Services billed
4,299
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 62% | |
| Diabetes | 34% | |
| Ischemic heart disease | 30% | |
| Chronic kidney disease | 30% | |
| Atrial fibrillation | 21% | |
| COPD | 21% | |
| Heart failure | 19% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 | Office | 22 | 40 | $196 |
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 29 | 1,922 | $188 |
| Injection, methylprednisolone acetate, 40 mg J1030 | Office | 16 | 20 | $71 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 11 | 45 | $4 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
73 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Podiatrist, Primary Podiatric Medicine in Indiana
Sean Rhodes
Podiatrist, Primary Podiatric Medicine · Warsaw, IN
Melanie Kocevar
Podiatrist, Primary Podiatric Medicine · Huntington, IN
Daniel Chianese
Podiatrist, Primary Podiatric Medicine · Wabash, IN
Manjit Kaur
Podiatrist, Primary Podiatric Medicine · Avon, IN
Timothy Quist
Podiatrist, Primary Podiatric Medicine · Elkhart, IN
Tanisha Smith
Podiatrist, Primary Podiatric Medicine · Indianapolis, IN
Related records
Podiatrist, Primary Podiatric Medicine in Indiana
Practitioners in the same specialty and state, ranked by reported value.
All Podiatrist, Primary Podiatric Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Indiana
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.